top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Smart Insulin Pens Market Trends Outlook, Trend, Growth and Share Estimation Analysis

0 votes
5 views

Transparency Market Research (TMR) has published a new report titled, “Smart Insulin Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global smart insulin pens market was valued at US$ 29.2 Mn in 2018. It is projected expand at a CAGR of 10.3% from 2019 to 2027. Increase in the prevalence of diabetes, rise in awareness about chronic diseases, such as diabetes, and surge in adoption of connected medical devices are anticipated to augment the global market between 2019 and 2027.

Smart insulin pens are used to deliver insulin for the treatment of type 1 and type 2 diabetes. Smart insulin pens have additional features such as memory function, time and dose recorder, and data transfer. Rise in prevalence of both type of diabetes in children and adults, due to obesity and changing lifestyle and dietary habits, is a key factor that is anticipated to drive the global market for smart insulin pens. Additionally, technological advancements and integration of glucose monitoring and therapeutics for better diabetes management are likely to propel the global smart insulin pens market. However, availability of alternatives for insulin delivery is anticipated to restrain the global market.

The report offers detailed segmentation of the global smart insulin pens market based on product, connectivity type, application, and distribution channel. The market has also been segmented based on region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Adoption of technological advancements and increase in prevalence of diabetes are likely to drive the global smart insulin pens market.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35705

Adaptors for conventional pens segment to account for leading share, while smart insulin pens segment expand significantly

In terms of product, the adaptors for conventional pens segment accounted for a leading share of the global market in 2018, and the trend is anticipated to continue during the forecast period. Increase in prevalence of diabetes in people of all ages across the globe is projected to boost the segment during the forecast period. Expansion of the smart insulin pens segment is attributed to technological advancements such as memory function and accurate dose administration.

Technological advancements in smart insulin pen to propel market

Emerging technologies in smart insulin pens are projected to boost the global smart insulin pens market during the forecast period. iSenz is an adaptor for smart insulin pens that possess a feature to detect the insulin level, by scanning. It provides the correct angles for injections in order to optimize the injection sites for diabetes. Easylog is an adaptor for insulin pens connected via the internet. This product provides the right dose and offers better comfort to the patient for the treatment of chronic diseases such as diabetes. InsulCheck, is cap for insulin pens that contains a sensor to track pen usage and temperature.

Buy Now Smart Insulin Pens Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=35705&ltype=S

North America to be highly lucrative smart insulin pens market

North America has a large number of smart insulin pens approved for the treatment of diabetes. In the U.S., significant increase in the prevalence of diabetes is likely to propel the region’s leading share of the global market during the forecast period. Additionally, product launches and approval for smart insulin pens are anticipated to drive the market in the region.

Product launches by key players and patent approvals to boost market

The report also provides profiles of leading players operating in the global smart insulin pens market. These include Novo Nordisk A/S, Sanofi (sanofi-aventis US LLC), Eli Lilly and Company, Companion Medical, Emperra GmbH E-Health Technologies, Diabnext, Jiangsu Delfu medical device Co.,Ltd, BERLIN-CHEMIE, DIAMESCO CO., Ltd., and Patients Pending Ltd (Bigfoot Biomedical Inc.). In July 2018, Companion Medical, a provider of advanced technological products for diabetes, received approval from Food and Drug Administration for InPen in the U.S. This product approval enabled the company to strengthen its digital diabetes products portfolio in the U.S. In March 2018, sanofi-aventis U.S. LLC received approval from U. S. Food and Drug Administration for Toujeo Max SoloStar. This product approval enabled the company to strengthen its product portfolio.

More Trending Reports by Transparency Market Research –

ePharmacy Market: prnewswire.com/news-releases/epharmacy-market-to-reach-us128-billion-by-2023-transparency-market-research-560938961.html

Canada Home Healthcare Market: prnewswire.com/news-releases/canada-home-healthcare-market-set-to-reach-us1894-bn-by-the-end-of-2020-transparency-market-research-565741581.html

posted Feb 13 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report on the systemic lupus erythematosus treatment market for the forecast period of 2019–2027. According to the report, the global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018, and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Systemic Lupus Erythematosus Treatment Market: Overview

  • Growth of the global systemic lupus erythematosus treatment market can be attributed to rise in the incidence of systemic lupus erythematosus, and promising drug pipeline and approvals.
  • North America dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, and the presence of major market players are expected to drive the market in North America.
  • Asia Pacific is expected to be a highly lucrative market for systemic lupus erythematosus treatment, expanding at a high CAGR during the forecast period.

Immunosuppressive Drugs to Dominate Market

  • Based on drug, the global systemic lupus erythematosus treatment market has been divided into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, immunosuppressive drugs, and others (biologics, B-cell modulators, etc.).
  • The immunosuppressive drugs segment dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is likely to continue during the forecast period.
  • Immunosuppressive drugs such as azathioprine, cyclophosphamide, and methotrexate help control inflammation and the overactive immune system in the treatment of SLE. Furthermore, increase in the popularity of methotrexate as a treatment option is likely to boost the growth of this segment.
  • The immunosuppressive drugs segment can be further segmented into azathioprine, cyclophosphamide, methotrexate, and others. In terms of immunosuppressive drugs, the azathioprine sub-segment is anticipated to dominate the market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73932

Oral Mode of Delivery to be Popular

  • In terms of mode of delivery, the global systemic lupus erythematosus treatment market can be divided into intravenous, subcutaneous, and oral.
  • The oral segment dominated the global systemic lupus erythematosus treatment market, due to an increase in the preference for self-administration of drugs such as immunosuppressive drugs, antimalarial drugs, and corticosteroids. This, in turn, is projected to drive the segment during the forecast period.
  • Furthermore, major market players are focusing on the launching of new products in the tablet and capsule form. This is likely to boost the growth of the segment during the forecast period.
  • The intravenous segment is expected to be a highly lucrative segment of the market during the forecast period. The intravenous route helps in the immediate delivery of drug, and since the delivery is into a vein, the drug starts working immediately. Moreover, drug degradation is less as compared to the oral route of administration.

Retail Pharmacies Accounted for Major Share of Market

  • Based on distribution channel, the global systemic lupus erythematosus treatment market has been segmented into hospital pharmacies, retail pharmacies, and online sales.
  • The retail pharmacies segment dominated the global systemic lupus erythematosus treatment market in terms of revenue in 2018, and the trend is projected to continue during the forecast period. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, such as NSAIDS, antimalarial drugs, and corticosteroids, as OTC drugs in retail stores, are likely to propel this segment during the forecast period.
  • Hospital pharmacies is expected to be the second-most lucrative segment of the global systemic lupus erythematosus treatment market during the forecast period. The segment is expected to expand at a significant CAGR from 2019 to 2027,due to an increase in the demand for recently launched new products for systemic lupus erythematosus treatment.

Buy Now Systemic Lupus Erythematosus Treatment Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=73932&ltype=S

North America to Dominate Global Market

  • In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global systemic lupus erythematosus treatment market in 2018, followed by Europe.
  • North America accounted for a major share of the global systemic lupus erythematosus treatment market in 2018, owing to an increase in the use of systemic lupus erythematosus treatment products, especially for various symptoms of the disease. Additionally, the launch of new products by major pharmaceutical manufacturers fuels the market in this region.
  • The systemic lupus erythematosus treatment market in Asia Pacific is likely to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in the prevalence of systemic lupus erythematosus, improving healthcare infrastructure in terms of better facilities, and rise in the demand for advanced products. According to a latest study, the prevalence was in the range of 4.3 to 45.3/100,000 person per year.

Systemic Lupus Erythematosus Treatment Market: Competitive Landscape

  • The global systemic lupus erythematosus treatment market is fragmented in terms of number of players.
  • Key players operating in the global market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC, and Aurinia Pharmaceuticals, Inc.

More Trending Reports by Transparency Market Research –

Non-invasive Prenatal Testing Market: prnewswire.com/news-releases/non-invasive-prenatal-testing-market-to-cross-us-5-000-million-by-2027—says-tmr-300865294.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

Global Hematology Market: Snapshot

The strides in the global hematology market have been catalysed by multiple distinct factors. Advances in diagnostic technologies for hematologic malignancies and automation in devices have helped address current and emerging needs of patients in the hematology market. Over the past few years, new paradigms in medicine and health care have increasingly broadened the market potential. Hematology care encompassed by oncology, immunology, and molecular biology is opening new avenues in the hematology market. A case in point is through understanding of hematopoietic stem cells.

An understanding of success of specific treatments for haematological disorders has further quality of care in the hematology market.  Advances in cancer immunotherapy protocols play crucial role in shaping the contours of the market.

Global Hematology Market: Notable Developments

Recent spate of research has shed light on various types of risks for hematologic malignancies. Of these, familial relative risk (FRR) has been drawing the attention of researchers, which might pave way for new avenues in the hematology market. A recent study obtained 153,115 records of hematologic malignancies through Swedish Family-Cancer Database over nearly 70 years from 1958 to 2015. The researchers measured familial relative risks in the patients. The study highlighted some interesting results. FRR was higher in certain tumor types, in conditions when multiple relatives of individuals were affected, particularly when first-degree relatives were affected. Also the FRR was higher when relatives were diagnosed with myeloid malignancies at an earlier age.

Request PDF Sample of Hematology Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73364

The results have gained significance in the hematology market to devise appropriate diagnostic modules and identification of high-risk patients. This will boost awareness about the familial risks among patients and their families and clinicians.

Some of the prominent key players in the hematology market are:

  • Thermo Fisher Scientific Inc.
  • Fluidigm Corporation
  • F.Hoffmann-La Roche AG
  • Danaher Corporation
  • Bio-Rad Laboratories Inc.
  • Agilent Technologies Inc.
  • Abbott Laboratories

 Global Hematology Market: Growth Dynamics

Blood disorders are a substantial health and economic burden in worldwide populations. Growing prevalence of common blood disorders such as anaemia particularly among women, and haemophilia has been driving clinical advances in the hematology market. Prevalence of certain blood cancer in developed countries is also bolstered awareness for hematology testing. Increasing inclination of hematology care providers in automating testing technologies has opened lucrative avenues for device manufacturers, notably in emerging economies. Growing incidence of genetic blood disorders is also boosting the hematology market.

Over the years, interested stakeholders in the hematology market have benefitted from advances in understanding the biology of hematopoietic stem cells. An expanding cancer immunotherapy protocols have also expanded the potential of the market. Emerging area of induced pluripotent stem (iPS) cells will likely open new doors of opportunities in the not-so-distant future.

Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Hematology Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=73364

The advent of instruments that help clinicians measure patient-reported outcomes (PRO) has taken the quality of care in the hematology market to a new trajectory. These outcomes are of vital prognostic value as they enable clinicians to incorporate patients’ perspective in the treatment process. PRO assessments are gathering steam in clinical trials as well as clinical practice.

Global Hematology Market: Regional Analysis

Among the various regions, North America has been showing vast revenue generating potential. Rising concern of blood-related disorders, notably in the U.S., and constant research for developing cutting-edge instruments have reinforces the prospects of the region in the hematology market. Meanwhile, Europe and Asia Pacific are potentially promising regional markets, with the latter showing considerable appetite for growth. Growing awareness of hematologic disorders and improving oncology care are aspects augmenting the prospects of the regional market. Advances made in transplant biology and immunology in Europe will help open numerous lucrative avenues in the region in the coming few years.

More Trending Reports by Transparency Market Research –

Automated Sample Storage Market: prnewswire.com/news-releases/automated-sample-storage-market-to-reach-us1950-million-by-2025-rising-government-support-to-remain-vital-driver-641617163.html

Menopausal Hot Flashes Market: prnewswire.com/news-releases/menopausal-hot-flashes-market-to-reach-us528-bn-by-2023-estrogen-leads-hormonal-products-in-revenue-and-prescription-volume-564235661.html

0 votes

Transparency Market Research (TMR) has published a new report titled, “Anticoagulants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global anticoagulants market was valued at US$ 21,759.3 Mn in 2018 and is projected to expand at a CAGR of 8.0% from 2018 to 2026. Rise in prevalence of obesity, increase in hip and knee surgeries, and surge in cases of coagulation disorders are anticipated to boost the growth of the global market from 2018 to 2026. 

Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. 

Increase in Geriatric Population

Dwindling birth rates have led to an increase in the geriatric population. In Japan, people aged 65 and above currently constitute 23% to 25% of the total population. The percentage is projected to reach 38% by 2050. In North America, the estimates are between 13% and 22% and between 16% and 27% in Europe. Rise in standard of health care facilities and availability of advanced treatment options boost life expectancy rates across the world. This in turn increases the geriatric population. According to the UN Population Division, the number of people aged 60 and above is anticipated to increase significantly during 2015–2030.

Request PDF Sample of Anticoagulants Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60924

In developed countries, the percentage of people aged 60 and above has increased from 12% in 1950 to 22% in 2011 and is expected to reach 32% by 2050. On the other hand, in developing countries, the percentage of people aged 60 and above increased from 6% in 1950 to 9% in 2011 and is likely to reach 20% by 2050. Aging makes people prone to fractures and injuries, as their bone density decreases, making them fragile and increasing their susceptibility to falls and arthritis-related fractures. Cardiovascular diseases, kidney disease, osteoporosis, rheumatoid arthritis, and osteoarthritis are common age-related disorders. People aged above 60 are more prone to diseases and disorders. These factors drive demand for anticoagulants products among the geriatric population. 

Rise in Cases of Coagulation Disorders

The rise in adoption of Novel Oral Anticoagulants (NOACs) boosts market growth. NOACs target either factor Xa to avoid or to treat thrombosis. These show rapid action and do not require constant monitoring. NOACs also have better efficacy and safety profiles than conventional therapies such as warfarin. Therefore, adoption rate of NOACs has increased in the global anticoagulant market.

Since the introduction of anticoagulants antidotes such as idarucizumab in the market in 2015, acceptance of NOACs has increased, as these eliminate the risk of bleeding. Xarleto and Eliquis are two anticoagulants increasingly preferred by physicians. Xarleto reported a Y-o-Y growth of nearly 10% in 2015, due to increase in volume in some of the key countries such as Japan and Germany. Sales of Eliquis rose by 140.3% due to increase in demand for NOACs globally. 

Buy Now “Anticoagulants Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=60924&ltype=S

Rise in Prevalence of Obesity

Obesity is a key factor for the rise in the number of people suffering from kidney disorders, cardiovascular disorders, and stroke. This is also attributed to changes in lifestyle and lack of physical activity. According to CDC 2015 report, nearly 950,000 people are affected by pulmonary embolism (PE) or deep vein thrombosis (DVT). Moreover, these conditions account for 65,000 to 100,000 deaths in the U.S. each year.

Additionally, more than 10% of the geriatric population of the U.S., which accounts for 25 million people, is affected by kidney diseases associated with thrombosis. This is because aging increases the risk of developing renal and cardiovascular diseases, with chances of thromboembolic and hemorrhagic events also rising. This condition is treated using anticoagulants. Increase in the number of people suffering from DVT and surge in number of surgeries are expected to drive the global anticoagulants market.

Increase in Hip and Knee Surgeries

Rise in the number of knee and hip replacement surgeries increases the risk of DVT. For example, surgeries often result in long period of immobility, which increases the chances of developing DVT due to less blood flow in the body. According to CDC 2016 report, over a million people in the U.S. undergo hip and knee replacement surgeries each year. Moreover, the number of surgical procedures has increased among the geriatric population across the globe. Rise in the number of surgeries increases the risk of developing thromboembolic events. This drives demand for treatment using anticoagulants among patients.

North America to Dominate Global Market

Rise in surgical procedures such as hip and knee replacements is projected to increase the patient pool for treatment with anticoagulants in North America and Europe. According to the Centers for Disease Care and Prevention (2015), around 719,000 knee replacement and 332,000 hip replacement surgeries were performed in the U.S. in 2014. Asia Pacific is expected to be the most lucrative market for anticoagulants from 2018 to 2026. Increase in disposable income, rise in population, and expansion of key players in the region are likely to boost the growth of the anticoagulants market in Asia Pacific.

0 votes

Transparency Market Research (TMR) has published a new report titled, “Orthopedic Implants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the new report, the global orthopedic implants market is projected to expand at a CAGR of 4.4% from 2018 to 2026.

Technological advancements in terms of highly efficient product development and increase in competition among the leading players is positively impacting the global orthopedic implants market while benefitting patients. Increase in the global geriatric population which is more susceptible to musculoskeletal disorders such as osteoporosis, osteonecrosis, osteoarthritis, rheumatoid arthritis, and Perthes Disease is projected to boost demand for orthopedic implants during the forecast period.

North America dominated the global orthopedic implants market in 2017 and trend is anticipated to continue during the forecast period. This is attributed to favorable reimbursement for orthopedic procedures and rise in focus of key players on the development of new implants in the market. Increase in the geriatric population and rise in prevalence of osteoporosis in countries such as Japan, China, and India are expected to boost the market in Asia Pacific from 2018 to 2026.

Request PDF Sample of Orthopedic Implants Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26009

Product Recalls to Hamper Market

Product recalls due to device inefficiency or manufacturing errors affect the adoption rate among surgeons and patients, which in turn hampers sales. Recalls and associated lawsuits have criticized orthopedic companies leading to loss of reliability in the minds of customers. For example, in December 2016, Greatbatch Medical, a subsidiary of Integer Holdings Corporation, recalled standard offset cup impactor device which is used for hip joint replacement. The device failed the sterility test which can lead to infection in patients during surgery.

Joint Reconstruction Segment to Lose Market Share

The report offers detailed segmentation of the global orthopedic implants market based on product and end-user. In terms of product, the joint reconstruction segment is projected to dominate the global market due to increase in the number of hip and knee replacement procedures and presence of major players. According to a report published by the American Academy of Orthopedic Surgeons (AAOS), the U.S. reported 17% increase in total knee arthroplasties, 37% in total hip arthroplasties, and 66% in unicompartmental knee arthroplasties in 2015. However, the segment is expected to lose market share during the forecast period owing to stringent FDA regulations for product approvals and high investments. The orthobiologic implants segment is anticipated to gain market share by 2026.

Hospitals and Orthopedic Clinics to be Top End-user Segments

In terms of end-user, the hospitals segment is projected to account for major share of the global orthopedic implants market during the forecast period. This is attributed to ease of availability of instruments and facilities required for the orthopedic procedures present in hospitals and favorable reimbursement policies. The orthopedic clinics segment is anticipated to expand at a high CAGR due to changing preference from hospitals to orthopedic clinics owing to advancements in clinics in terms of facility requirements. Shorter hospital stay, quality of procedures and care, availability of emergency minimal invasive surgeries, and advanced implants are likely to propel the segment during the forecast period.

Enquiry for Discount on “Orthopedic Implants Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26009

North America Market to Grow at Rapid Pace and Create High Incremental Opportunity

In terms of revenue, North America held a major share of the global market in 2017. This is attributed to high health care expenditure and rise in awareness about the advantages of different orthopedic implants in the U.S. Additionally, presence of several players such as Stryker and Zimmer Biomet Holdings, Inc. with significant investment in research & development of advanced implants is projected to propel the orthopedic implants market in North America from 2018 to 2026. Moreover, high acceptance of minimally invasive hip replacements, higher adoption of cementless hips despite significant costs involved, improved survival rates, and rise in preference for reverse hybrid hip replacement procedures are likely to propel the orthopedic implants market in the region.

Rise in incidence of orthopedic diseases and improving economy in China, India, and other countries in Southeast Asia resulting in high per capita health care expenditure are anticipated to drive the orthopedic implants market in Asia Pacific. Changes in the market composition, policy and regulatory environments will alter the landscape in the near future. The market in the developing regions is characterized by domestic as well as international players.

Market share of international players in countries such as China and India is increasing at a rapid pace owing to merger and acquisition activities and new product launches in the region. According to the International Osteoporosis Foundation, the rate of incidence of hip fractures among the people of Asia increased 4-fold to 5-fold in 2013. This is also likely to fuel the growth of the market in Asia Pacific. Economic growth in countries such as Brazil is increasing research & development activities and expenditure on treatment in Latin America. These factors are likely to propel the global orthopedic implants market in Latin America.

Zimmer Biomet Holdings, Inc., DePuy Synthes, and Stryker to Dominate Market

The report provides profiles of leading players operating in the global orthopedic implants market. These include Zimmer Biomet Holdings, Inc., DePuy Synthes, Stryker, Smith & Nephew, Medtronic Spinal, DJO Global, Arthrex, Inc., NuVasive, Inc., and Globus Medical. Expansion of portfolio by developing new products or through acquisition and licensing agreements to develop products is a key strategy adopted by these players. For instance, in September 2016, Stryker entered into an agreement to acquire the assets of Instratek, Inc., a U.S.-based orthopedic implants and endoscopic instrumentation manufacturer. This acquisition strengthened Stryker’s presence in the forefoot and upper extremity segments.

Other key players are also adopting similar strategies. Large number of global manufacturers are putting constant efforts in the development and manufacture of novel orthopedic products to meet the medical need of patients. Demand for advanced technologies such as minimally invasive surgery (MIS), navigation technology, 3D bioprinting and tissue engineering, and custom made implants is increasing. Key players are focusing on the development of new implants with better efficacy. For instance, Medtronic launched the titanium 3D printed platform, TiONIC Technology, which enables incorporation of integrated surface technologies and complex designs in spine surgery implants. Such key developments are likely to augment the global orthopedic implants market in the near future.

0 votes

The global oncology biosimilars market is prophesied in a report by Transparency Market Research (TMR) finds highly competitive and highly fragmentation owing to presence of strong players in the market. In order to acquire substantial share and to be part of such intense competition, these key players have adopted strategies such as frequent mergers and acquisitions, product innovations, and geographical expansion. Leading companies in the global oncology biosimilars market that are profiled in this report are Biocon, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and BIOCAD.

The global oncology biosimilars market to expect to expand with a CAGR of 27.5% from 2017 to 2025, for the market to attain the value of US$17,478.2 mn by the end of forecast period considerably up from registered value of US$2,100 mn in 2016.

Request PDF Sample of Oncology Biosimilars Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14696

On the basis of disease indication, neutropenia dominates the market owing to patent expiration of well-known oncology biologics coupled with efforts from several governments for developing affordable medicines available to patients. On the basis of region, Asia Pacific accounts for the significant share of the oncology biosimilars market in 2016 owing to availability of cost effective cancer medications with minimal side effects via retail stores in this region.

Rising Initiatives to Meet Up Demand for Inexpensive Cancer Therapies to Drive Growth

Increasing number of prevalence’s of for cancer such as breast cancer, lung cancer, cervical cancer, and stomach cancer is boosting demand for the proper treatment of every type of the caner, in turn is expected to drive the global oncology biosimilars treatment market over the forecast period.

The oncology biosimilars market is projected to be beneficial from rising demand for inexpensive cancer therapies. Cancer is the costliest health disease in terms of diagnosis and treatment. Pharmaceutical companies present worldwide are focused on development of biosimilars and generic medicines to fight cancer at all stages and for the one full treatment of the disease.

Buy Now “Oncology Biosimilars Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=14696&ltype=S

Efforts of Key Players to Widen Their Offerings and Patent Expiration to Boost Growth

Increasing number of alliances for development of biosimilar is expected to propel the growth of oncology biosimilars market over the forecast period. Oncology biosimilars are the versions of biologics which are manufactured by numerous companies and has been officially approved for cancer treatment. They are cost-effective and efficient as the original biologic. Adoption of oncology biosimilars for the treatment of cancer is boosting growth of the global oncology biosimilars market.

Additionally, increasing number of product approvals for treatment of various types of cancer is anticipated to fuel the growth of the market. However, complex manufacturing process and its approval is the major factor restraining growth of the global oncology biosimilars market. Nevertheless, patent expiration is creating lucrative opportunities for the key players in the global oncology biosimilars market.

...